CAR-T Therapies for Blood Cancers Market Expands Rapidly with 18.90% CAGR Through 2035

According to Precedence Research, the global CAR-T therapies for blood cancers market size was valued at USD 6.80 billion in 2025 and is projected to grow from USD 8.09 billion in 2026 to approximately USD 38.40 billion by 2035, expanding at a strong CAGR of 18.90% from 2026 to 2035.

The rapid rise of CAR-T cell therapy adoption is being driven by its proven effectiveness in treating relapsed and refractory blood cancers, where traditional chemotherapy and radiation treatments often fail. Advances in gene editing, artificial intelligence, biomarker discovery, and next-generation cell engineering are further accelerating innovation across the oncology ecosystem.

As pharmaceutical and biotechnology companies continue investing heavily in research and commercialization, the CAR-T therapies for blood cancers market is expected to remain one of the fastest-growing sectors in advanced cancer therapeutics.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉 https://www.precedenceresearch.com/sample/8377

How is Artificial Intelligence Transforming the CAR-T Therapies Market?

Artificial intelligence is playing a major role in enhancing the efficiency and effectiveness of CAR-T therapies. AI-driven algorithms help researchers identify tumor-specific antigens by analyzing massive genetic and clinical datasets, enabling more accurate CAR-T target discovery and therapy customization.

Machine learning tools are also improving patient selection by identifying individuals most likely to benefit from CAR-T treatment. This predictive capability helps reduce treatment failures and optimize clinical outcomes.

Additionally, AI is streamlining manufacturing workflows by improving T-cell engineering, monitoring quality control, and enhancing gene-editing precision. As manufacturing remains one of the biggest cost barriers in CAR-T therapy, AI-driven automation is expected to significantly reduce production timelines and operational complexities in the coming years.

CAR-T Therapies for Blood Cancers Market Key Growth Drivers

🔸 Rising Demand for Personalized Cancer Treatment: CAR-T therapies are redefining cancer care by offering highly personalized treatment approaches tailored to individual patients. By genetically engineering T-cells to target cancer-specific antigens, these therapies deliver improved response rates and durable remission outcomes, especially in difficult-to-treat blood cancers.

🔸 Increasing Incidence of Hematologic Malignancies: The growing global burden of leukemia, lymphoma, and multiple myeloma is significantly boosting demand for advanced immunotherapies. Aging populations and improved cancer diagnostics are further contributing to market expansion.

🔸 Advancements in AI and Gene Editing: Artificial intelligence and machine learning are streamlining CAR-T therapy discovery, improving manufacturing consistency, and enhancing treatment precision. Innovations in CRISPR-based gene editing are also enabling the development of safer and more effective next-generation therapies.

🔸 Expanding Regulatory Approvals: Regulatory bodies are increasingly approving CAR-T therapies for broader clinical applications, accelerating adoption across hospitals and specialty cancer centers globally.

🔗 What's Fueling the Next Wave of Growth? 👉 https://www.precedenceresearch.com/car-t-therapies-for-blood-cancers-market

CAR-T Therapies for Blood Cancers Market Opportunities

🔸 Expansion of Allogeneic CAR-T Therapies: Allogeneic CAR-T therapies present significant growth opportunities due to their off-the-shelf availability, reduced costs, and faster delivery timelines. These therapies are expected to improve scalability and accessibility across global healthcare systems.

🔸 Growth in Emerging Markets: Countries across Asia-Pacific and Latin America are investing heavily in biotechnology infrastructure and advanced cancer care, creating strong opportunities for market expansion.

🔸 Next-Generation Multi-Antigen Therapies: Dual-target and multi-antigen CAR-T therapies are expected to gain strong traction as they improve efficacy and reduce relapse risks.

🔸 AI-Driven Manufacturing and Automation: The integration of AI-driven manufacturing systems is expected to reduce production bottlenecks, improve quality control, and lower overall therapy costs.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

CAR-T Therapies for Blood Cancers Market Trends

The CAR-T therapies for blood cancers market is undergoing rapid transformation as precision medicine becomes central to oncology treatment strategies worldwide. One of the most influential trends shaping the industry is the growing use of artificial intelligence in CAR-T therapy development. AI-powered analytics are enabling researchers to identify tumor-specific antigens faster, optimize CAR designs, improve patient selection, and streamline manufacturing workflows.

Another major trend is the increasing focus on allogeneic "off-the-shelf" CAR-T therapies. Unlike autologous therapies that rely on patient-derived cells, allogeneic approaches use donor cells, significantly reducing production timelines and improving treatment accessibility. These therapies are gaining traction due to their scalability and cost advantages.

Gene-editing technologies such as CRISPR-Cas are also transforming the CAR-T landscape by improving therapy precision, minimizing relapse risks, and enhancing long-term treatment outcomes. Additionally, dual-target and multi-antigen CAR-T therapies are emerging as next-generation innovations capable of overcoming antigen escape and improving tumor recognition.

Regulatory agencies worldwide are expanding approvals for CAR-T therapies across additional indications and earlier treatment lines, creating broader patient access. Simultaneously, collaborations between pharmaceutical companies, biotechnology firms, research institutes, and healthcare providers are accelerating product development and commercialization.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉 https://www.precedenceresearch.com/checkout/8377

CAR-T Therapies for Blood Cancers Market Regional Analysis

North America dominated the CAR-T therapies for blood cancers market with a 50% market share in 2025. The region benefits from strong healthcare infrastructure, early adoption of advanced therapies, high cancer prevalence, and the presence of leading CAR-T therapy manufacturers. Robust clinical research ecosystems and favorable regulatory pathways have also accelerated commercialization.

The United States remains the largest contributor within the region due to rising incidences of lymphoma and multiple myeloma, increased biotech investments, and accelerated FDA approvals.

Asia Pacific is projected to grow at the fastest CAGR of 22.5% from 2026 to 2035. Growth is fueled by rising cancer cases, expanding clinical trial activity, improving healthcare infrastructure, and strong government support for biotechnology innovation.

Countries such as China and India are rapidly emerging as key CAR-T therapy markets due to their large patient populations and increasing investments in cell therapy manufacturing.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@ https://www.precedenceresearch.com/sample/8377

CAR-T Therapies for Blood Cancers Market Segment Analysis

🔹 Target Antigen Analysis

The CD19-targeted CAR-T segment dominated the CAR-T therapies for blood cancers market in 2025, holding a 45% share. Its leadership is driven by strong clinical efficacy, multiple regulatory approvals, and proven effectiveness in treating leukemia and lymphoma. As a well-established target in B-cell malignancies, CD19 therapies continue to show high response rates and durable outcomes, especially in relapsed or refractory cases.

The BCMA-targeted CAR-T segment accounted for a 30% share in 2025 and is expected to grow rapidly due to strong clinical success in multiple myeloma. BCMA has emerged as a highly promising target for relapsed or refractory patients, supporting increased adoption.

The CD20-targeted CAR-T segment held a 10% share and is projected to grow steadily, supported by ongoing clinical trials in B-cell lymphomas. Meanwhile, dual-target and multi-antigen CAR-T therapies held a 15% share in 2025 and are expected to grow at the fastest rate. These advanced therapies improve tumor targeting, reduce relapse risk, and benefit from progress in gene editing and synthetic biology.

🔹 Cancer Type Analysis

Diffuse large B-cell lymphoma (DLBCL) led the market in 2025 with a 35% share. Its dominance is due to its high prevalence and strong clinical outcomes from CAR-T therapy, particularly in relapsed or refractory cases where it has become a standard treatment option.

Multiple myeloma held a 30% share and is expected to grow fastest due to increasing demand for BCMA-targeted therapies and limited existing treatment options. Acute lymphoblastic leukemia (ALL) accounted for a 20% share, driven by early success in pediatric and refractory cases.
Chronic lymphocytic leukemia (CLL) held a 10% share, with steady growth supported by ongoing clinical trials and combination therapy research aimed at improving response rates.

🔹 Therapy Type Analysis

Autologous CAR-T therapies dominated the market with an 80% share in 2025. Their leadership is supported by established manufacturing processes, regulatory approval, and strong clinical outcomes using a patient's own T-cells for personalized treatment.

Allogeneic CAR-T therapies held a 20% share but are expected to grow rapidly due to scalability, lower costs, and faster availability. These off-the-shelf therapies eliminate the need for individualized production, improving access for urgent cases.

🔹 End-Use Analysis

Hospitals led the market with a 50% share in 2025 due to their advanced infrastructure, skilled professionals, and ability to manage complex side effects such as cytokine release syndrome.

Specialty cancer treatment centers accounted for 35% of the market and are expected to grow fastest due to increasing demand for specialized oncology care and integrated cell therapy capabilities. Academic and research institutes held a 15% share, contributing significantly through clinical trials, innovation, and early-stage CAR-T development.

🔹 Manufacturing Type Analysis

In-house manufacturing dominated the market with a 60% share in 2025, offering better quality control, regulatory compliance, and supply chain management.

Contract manufacturing held a 40% share and is expected to grow rapidly due to rising outsourcing trends, scalability needs, and faster commercialization. Contract manufacturing organizations help accelerate production and market entry for CAR-T therapies.

✚ Related Topics You May Find Useful:

➡️ CAR-T Cell Therapy Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/car-t-cell-therapy-market

➡️ Automated and Closed Cell Therapy Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/automated-and-closed-cell-therapy-market

➡️ Cell Therapy Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/cell-therapy-market

➡️ Engineered T Cells Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/engineered-t-cells-market

➡️ Acute Lymphocytic Leukemia Therapeutics Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/acute-lymphocytic-leukemia-therapeutics-market

➡️ Blood Cancer Diagnostics Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/blood-cancer-diagnostics-market

➡️ Precision Oncology Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/precision-oncology-market

CAR-T Therapies for Blood Cancers Market Top Companies and Their Offerings

➢ Novartis AG
Kymriah (tisagenlecleucel): FDA‐approved CAR‐T therapy for relapsed/refractory B‐cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients and for certain adult diffuse large B‐cell lymphoma indications.

➢ Gilead Sciences, Inc. (Kite Pharma)
Yescarta (axicabtagene ciloleucel): FDA‐approved CAR‐T therapy for relapsed/refractory large B‐cell lymphoma and earlier‐line follicular lymphoma.

➢ Tecartus (brexucabtagene autoleucel): FDA‐approved CAR‐T therapy for relapsed/refractory mantle cell lymphoma and B‐cell ALL.

➢ Bristol Myers Squibb Company (Celgene / Juno Therapeutics)
Breyanzi (lisocabtagene maraleucel): FDA‐approved CAR‐T therapy for relapsed/refractory large B‐cell lymphoma and earlier‐line follicular lymphoma.

➢ Abecma (idecabtagene vicleucel): FDA‐approved CAR‐T therapy for relapsed/refractory multiple myeloma (developed with bluebird bio).

➢ Johnson & Johnson (Legend Biotech Corporation)
Carvykti (ciltacabtagene autoleucel): FDA‐approved dual‐targeting BCMA‐directed CAR‐T therapy for relapsed/refractory multiple myeloma.

➢ Fate Therapeutics, Inc.
iPSC‐derived off‐the‐shelf CAR‐T and NK‐cell product platforms (e.g., FT819, FT819‐based combinations) targeting hematologic malignancies (B‐ALL, lymphoma, etc.), primarily in clinical development.

➢ Allogene Therapeutics, Inc.
AlloCAR T platform offering allogeneic ("off‐the‐shelf") CAR‐T therapies for relapsed/refractory B‐cell lymphoma and other hematologic malignancies (e.g., ALLO‐501, ALLO‐501A, ALLO‐715).

➢ Cellectis S.A.
TALEN‐edited allogeneic CAR‐T therapies such as UCART19 (CD19‐directed) for B‐cell ALL and UCART123/UCARTCS1 (for AML and myeloma), in preclinical and early‐clinical stages.

➢ Bluebird Bio, Inc.
Co‐developed Abecma (ide‐cel) for multiple myeloma; the oncology cell‐therapy business has been divested to 2seventy bio/Bristol Myers Squibb, so bluebird now focuses on gene therapy for rare diseases.

➢ Autolus Therapeutics plc
Next‐generation CAR‐T programs (e.g., autologous CD19‐CAR products such as AUTO3) designed for improved safety and control in aggressive B‐cell leukemias and lymphomas.

➢ Precision BioSciences, Inc.
➢ ARCUS‐based allogeneic CAR‐T therapies (e.g., PBCAR0191) targeting CD19 for relapsed/refractory B‐cell malignancies, including lymphoma and leukemia.

➢ Adaptimmune Therapeutics plc
Next‐generation engineered T‐cell therapies combining T‐cell receptor (TCR) technology and CAR platforms; CAR‐T programs are mostly in preclinical and early R&D for hematologic cancers.

➢ CRISPR Therapeutics AG
CRISPR/Cas9‐edited allogeneic CAR‐T candidates (e.g., CTX110, CTX112, CTX130) in development for relapsed/refractory B‐cell lymphomas and other hematologic indications.

➢ Sana Biotechnology, Inc.
Engineered hypoimmune CAR‐T and related cell‐therapy platforms; SC262 is a CD22‐targeted CAR‐T asset in development for resistant B‐cell cancers.

➢ Caribou Biosciences, Inc.
CRISPR‐based allogeneic CAR‐T platforms; lead candidates such as CB‐101 (CD19‐targeted) and CB‐010 (CD19‐targeted with PD‐1 knockout) are being evaluated in clinical trials for relapsed/refractory B‐cell malignancies.

➢ Arcellx, Inc.
ARC‐SparX platform featuring dosable, controllable CAR‐T cells redirectable to multiple antigens; CART‐ddBCMA (BCMA‐targeted) is in clinical development for multiple myeloma, and other programs (e.g., anti‐CD123) are being explored for AML and other blood cancers.

Latest Industry Developments

🔸 In January 2026, Australian companies AdAlta and SHcell announced a collaboration to advance CAR-T therapy BZDS1901 for solid tumors, including Phase 1 clinical trials in Australia.

🔸 In December 2025, Bristol Myers Squibb Company launched Breyanzi for adult patients with relapsed or refractory marginal zone lymphoma, expanding CAR-T therapy applications across blood cancers.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8377

Segments Covered in the Report

🔹 By Target Antigen

CD19-targeted CAR-T Therapies
BCMA-targeted CAR-T Therapies
CD20-targeted CAR-T Therapies
Dual-target & Multi-antigen CAR-T Therapies

🔹 By Cancer Type

Acute Lymphoblastic Leukemia (ALL)
Diffuse Large B-Cell Lymphoma (DLBCL)
Multiple Myeloma
Chronic Lymphocytic Leukemia (CLL)
Other Hematologic Malignancies

🔹 By Therapy Type

Autologous CAR-T Therapies
Allogeneic (Off-the-shelf) CAR-T Therapies

🔹 By End-Use

Hospitals
Specialty Cancer Treatment Centers
Academic & Research Institutes

🔹 By Manufacturing Type

In-house Manufacturing
Contract Manufacturing (CDMO-based)

🔹 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.